After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

In Hans Christian Andersen's folktale, The Emperor's New Clothes, when a child cries out that the emperor is naked, he isn't revealing a secret. Everyone already knows it. What changes in that instant ...

The Waterfall framework and the Agile software development process are two competing software development approaches, and the two of them couldn't be more different. Here are the important highlights ...

Zohran Mamdani, the Democratic front-runner in the mayor’s race, plans if elected to replace the selective program, which became a symbol of segregation in public schools. By Emma G. Fitzsimmons and ...

This AI company isn't yet living up to the hype. Let's discuss Recursion Pharmaceuticals' performance over the past four years and whether the company can deliver solid returns in the future. It can ...

Iterative Health, a healthcare technology and services company advancing GI clinical research, and One GI®, a top physician-led management services organization (MSO) and portfolio company of Webster ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min New Opportunity Zones criteria ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q2 2025 Earnings Call Transcript August 5, 2025 Recursion Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.41187 EPS, ...